Immunomodulation and Multiple Sclerosis Epidemiology

Trial Profile

Immunomodulation and Multiple Sclerosis Epidemiology

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Sep 2014

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms IMSE
  • Most Recent Events

    • 29 Sep 2009 New trial record
    • 10 Sep 2009 One year results have been presented at ECTRIMS 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top